FindTrial
Sign In

The real word study of safety and efficacy of etanercept in psoriatic arthritis patients

A multicenter, prospective, observational study on the safety and efficacy of etanercept in the treatment of psoriatic arthritis in the real world

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027001
Enrollment
Unknown
Registered
2019-10-28
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis

Interventions

Case series:etanercept

Sponsors

The First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged >=18 years old; 2. meet the diagnostic classification standard of GRAPPA in 2008. 3. prepare or start treatment with etanercept.

Exclusion criteria

Exclusion criteria: 1. pregnant and lactating women; 2. in the period of systemic acute and chronic infection, or have a history of active tuberculosis; 3. malignant tumor subjects; 4. other researchers think that the tested drug is not suitable.

Design outcomes

Primary

MeasureTime frame
PASI;—

Countries

China

Contacts

Public ContactPingting Yang

The First Affiliated Hospital of China Medical University

ypt1028@163.com+86 13904003875

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026